Kevin Zablonski/LinkedIn, William Archibald/LinkedIn
Jul 23, 2026, 19:25
William Archibald: Key Takeaways on VTE Cost-Effectiveness and Cancer Associated Thrombosis from ISTH 2026
William Archibald, Assistant Professor of Medicine at Wilmot Cancer Institute, shared a post on LinkedIn:
“Back home in Rochester from a very successful International Society on Thrombosis and Haemostasis (ISTH) 2026 where Kevin Zablonski and I presented our work on the cost effectiveness of apixaban for extended prevention in provoked VTE (clinical benefit and cost effective from Medicare perspective!)
Look out for our highlights of ISTH 2026 coming to OncUpdates soon for practice changes in cancer associated thrombosis and thrombocytopenia
Looking forward to ISTH 2027 in Vancouver.”
Stay updated with Hemostasis Today.
-
Oct 28, 2026, 23:39Paul Tortland: What a New PRP Study Really Tells Us About Knee Osteoarthritis
-
Oct 28, 2026, 23:34Jawad Derbas: Comparing Mechanical and Pharmacomechanical VTE Prophylaxis in Spine Surgery
-
Oct 28, 2026, 23:31Giulio Maria Pasinetti: Aspirin Use Linked to Lower Dementia Risk in Older Adults With Specific Genetic Characteristics
-
Oct 28, 2026, 23:27Ralf Ludwig: Targeting Neutrophil-Driven Autoimmunity Through CDK Inhibition
-
Oct 28, 2026, 23:26Houda Moustaide: Great Discussions During Our Training Day on Thrombocytopenia in Pregnancy
-
Oct 28, 2026, 23:22Keith Berelowitz: Building Better Medicines by Listening to Patients With Bleeding Disorders
-
Oct 28, 2026, 23:19Nickie Enos: Blood Clots in Arteries and Veins Differ in Symptoms and Treatment
-
Oct 28, 2026, 23:17David Rosenblum: Can Concentrated PRP Actually Cause Scar Tissue?
-
Oct 28, 2026, 23:15Shueh Hao Lim: Advancing Multidisciplinary Care for Venous Thromboembolism in Malaysia